Majority of Metaplastic Breast Cancers May Be Targetable

Article
Conference|Miami Breast Cancer Conference (MBCC)

In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.

In this video from the 32nd Annual Miami Breast Cancer Conference, Sherri Z. Millis, PhD, a molecular science liaison at Caris Life Sciences, Phoenix, Ariz., discusses a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content
Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.

Determining the Next Steps Forward With BTK Inhibitors in Relapsed CLL

Ariana Pelosci
November 14th 2024
Article

Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.

THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung Cancer

Kyle Doherty
November 11th 2024
Article

Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.

Novel Combo Shows Early Activity in PD-L1–Resistant NSCLC, Melanoma

Russ Conroy
November 11th 2024
Article

Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.

Phase 1 data support further assessment of DK210 (EGFR) in solid tumors such as renal cell carcinoma and non–small cell lung cancer.

Novel Immunocytokine Shows Immune Activation in EGFR+ Solid Tumors

Courtney Flaherty
November 9th 2024
Article

Phase 1 data support further assessment of DK210 (EGFR) in solid tumors such as renal cell carcinoma and non–small cell lung cancer.